LISTSERV mailing list manager LISTSERV 16.5

Help for SCIENCE-FOR-THE-PEOPLE Archives


SCIENCE-FOR-THE-PEOPLE Archives

SCIENCE-FOR-THE-PEOPLE Archives


SCIENCE-FOR-THE-PEOPLE@LIST.UVM.EDU


View:

Message:

[

First

|

Previous

|

Next

|

Last

]

By Topic:

[

First

|

Previous

|

Next

|

Last

]

By Author:

[

First

|

Previous

|

Next

|

Last

]

Font:

Proportional Font

LISTSERV Archives

LISTSERV Archives

SCIENCE-FOR-THE-PEOPLE Home

SCIENCE-FOR-THE-PEOPLE Home

SCIENCE-FOR-THE-PEOPLE  November 2003

SCIENCE-FOR-THE-PEOPLE November 2003

Subject:

[corp-focus] Say No to Silicone

From:

Phil Gasper <[log in to unmask]>

Reply-To:

Science for the People Discussion List <[log in to unmask]>

Date:

Fri, 7 Nov 2003 15:56:59 -0800

Content-Type:

text/plain

Parts/Attachments:

Parts/Attachments

text/plain (161 lines)

Say No to Silicone
By Russell Mokhiber and Robert Weissman

Eleven years ago, the U.S. Food and Drug Administration announced it was
pulling silicone breast implants from the market, leaving them available
only to breast cancer survivors who needed them for reconstruction or to
women enrolled in limited clinical studies.

The reason for the action, announced then-FDA Commissioner David
Kessler, was that, under the law, "these types of products have to be
shown by their manufacturer to be safe and effective before they may be
distributed and used.  Some people argue that the devices have to be
proven unsafe before the FDA can act to protect patients against their
use. This is not so. The burden of proof is an affirmative one and it
rests with the manufacturer. In this instance, the manufacturers have
not shown these devices to be safe."

Although silicone breast implants had been on the market for three
decades, Kessler said, "the list of unanswered questions is long."

"We do not know how long these devices will last," he said.

"We know that some of these implants will rupture, but we don't know how
many of them will rupture," he pointed out.

And, he said, "We don't know whether there is any link between the
implants and immune-related disorders and other systemic diseases."

"Until these basic questions are satisfactorily answered, we cannot
approve these devices."

Fast forward to the present.

Dow Corning, the leading manufacturer of silicone implants more than a
decade ago, is in bankruptcy.

Inamed, a California-based company, is now seeking marketing
authorization from the FDA for silicone breast implants.

More than a decade has passed since the FDA restricted sales of silicone
implants, but Inamed only submitted to FDA three years worth of data
from a study projected to continue for 10 years. The company sells
silicone implants in Europe and more than 60 countries worldwide, but it
hasn't collected any safety information from women in those countries
that is of high enough quality to submit to FDA.

As a result, we still don't know the answers to many of the questions
Kessler identified, and most of what we do know is frightening.

What we do know is that painful breast hardening which can lead to
deformity, dead tissue, loss of nipple sensation, infections and rashes
are common complications from silicone implants.

We know that rupture rates leading silicone to spread throughout the
body are extremely high over the long term -- occurring in more than
half or two thirds of women after 10 years, according to two studies.

We don't know whether there is any link between the implants and
immune-related disorders and other systemic diseases, though there is
worrying evidence that they do.

We started to ask Inamed spokesperson Peter Nicholson about these
matters, but he'd only say that the data Inamed submitted to the FDA was
available on the web, and the company would not be commenting further.

Inamed's data are indeed striking.

Even though the company reported on only three year's test results, the
numbers show significant short-term problems. After just three years,
one in five augmentation patients and almost half of reconstruction
patients required additional surgeries.

Inamed's data did not show particularly high rupture rates during the
three-year period of study -- in no small part because it only provided
MRIs to about a third of the women in the study, and silicone rupture
can only be detected through MRIs.

Inamed's data were replete with other flaws. For example, the company
misleadingly claimed a low incidence of lactation problems, by comparing
the incidence of problems to the overall population of women receiving
augmentation, not just those who tried to breastfeed.

These and other problems were pointed out by advocacy groups at an FDA
advisory committee hearing convened last month to issue a recommendation
on whether Inamedís marketing application should be approved.

The advisory committee also heard heart-wrenching testimony from more
than two dozen women with silicone implants. They described the extreme
pain and life-changing problems they have suffered as a result of
silicone implants in terms that could fail to move only those with
hardened hearts. And several highlighted an important economic component
-- health insurance plans generally do not cover surgeries to remove
implants for augmentation patients, placing a huge financial burden on
sick women.

Nonetheless, the advisory panel, a quarter of whom are plastic surgeons,
and at least one of whom was swayed by empty promises from Inamed to do
ongoing follow-up research, voted 9-6 to recommend the FDA approve
Inamedís request.

The failure for a larger majority to support the application leaves it
awkward for FDA to recommend approval.

Inamedís chances of approval worsened last week, when Dr. Thomas Whalen,
the non-voting chair of the advisory panel, in a highly unusual move,
sent a letter to FDA commissioner Mark McClellan. Whalen called the
panel decision "misguided," emphasizing the lack of data on long-term
safety. He felt "morally compelled" to urge the FDA to deny approval, he
told reporters.

Now the decision rests with FDA Commissioner Mark McClellan.

The law hasnít changed since the time the FDA ordered silicone implants
off the market. The agency faces the same choice it faced in 1992, with
little new information Ė and much of the recent information indicating
the implants' hazards.

If the FDA upholds its obligation under the law to approve products only
that afford "a reasonable assurance of safety," it has no choice but to
deny approval.

You can help influence the decision. Send a message to FDA Commissioner
McClellan urging him not to approve Inamedís application. You can do
this from the website of the Command Trust Network, an information
clearinghouse on implants, at: <http://www.commandtrust.org>.


Russell Mokhiber is editor of the Washington, D.C.-based Corporate Crime
Reporter, http://www.corporatecrimereporter.com. Robert Weissman is
editor of the Washington, D.C.-based Multinational Monitor,
http://www.multinationalmonitor.org. They are co-authors of Corporate
Predators: The Hunt for MegaProfits and the Attack on Democracy (Monroe,
Maine: Common Courage Press; http://www.corporatepredators.org).

(c) Russell Mokhiber and Robert Weissman

This article is posted at:
<http://lists.essential.org/pipermail/corp-focus/2003/000166.html>.
_______________________________________________

Focus on the Corporation is a weekly column written by Russell Mokhiber
and Robert Weissman. Please feel free to forward the column to friends or
repost the column on other lists. If you would like to post the column on
a web site or publish it in print format, we ask that you first contact us
([log in to unmask] or [log in to unmask]).

Focus on the Corporation is distributed to individuals on the listserve
[log in to unmask] To subscribe,
unsubscribe or change your address to corp-focus,
go to:
<http://lists.essential.org/mailman/listinfo/corp-focus>
or send an e-mail
message to [log in to unmask] with your request.

Focus on the Corporation columns are posted at
<http://www.corporatepredators.org>.

Postings on corp-focus are limited to the columns. If you would like to
comment on the columns, send a message to [log in to unmask] or
[log in to unmask]

Top of Message | Previous Page | Permalink

Advanced Options


Options

Log In

Log In

Get Password

Get Password


Search Archives

Search Archives


Subscribe or Unsubscribe

Subscribe or Unsubscribe


Archives

January 2022
December 2021
November 2021
October 2021
September 2021
August 2021
July 2021
June 2021
May 2021
April 2021
March 2021
February 2021
January 2021
December 2020
November 2020
October 2020
September 2020
August 2020
July 2020
June 2020
May 2020
April 2020
March 2020
February 2020
January 2020
December 2019
November 2019
October 2019
September 2019
August 2019
July 2019
June 2019
May 2019
April 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
May 2018
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
August 2017
July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
December 2016
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
January 2016
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
March 2006
February 2006
January 2006
December 2005
November 2005
October 2005
September 2005
August 2005
July 2005
June 2005
May 2005
April 2005
March 2005
February 2005
January 2005
December 2004
November 2004
October 2004
September 2004
August 2004
July 2004
June 2004
May 2004
April 2004
March 2004
February 2004
January 2004
December 2003
November 2003
October 2003
September 2003
August 2003
July 2003
June 2003
May 2003
April 2003
March 2003
February 2003
January 2003
December 2002
November 2002
October 2002
September 2002
August 2002
July 2002
June 2002
May 2002
April 2002
March 2002
February 2002
January 2002
December 2001
November 2001
October 2001
September 2001
August 2001
May 2001
March 2001
February 2001
January 2001
December 2000
November 2000
October 2000
September 2000
August 2000
July 2000
May 2000
April 2000
March 2000
February 2000
January 2000
December 1999
November 1999
October 1999
September 1999
August 1999
July 1999
June 1999
May 1999
April 1999
March 1999
February 1999
January 1999
December 1998
November 1998
September 1998
August 1998
July 1998
June 1998
May 1998

ATOM RSS1 RSS2



LIST.UVM.EDU

CataList Email List Search Powered by the LISTSERV Email List Manager